Para a página inicial

Os 86 melhores médicos de imunoterapia com keytruda (pembolizumab) do mundo

O conteúdo segue a Política Editorial da Bookimed e foi revisado por

Fahad Mawlood

Herishanu Yair

  • 4.5 Bom • 172 avaliações
  • 24 anos de experiência
  • Israel, Telavive, Sourasky Medical Center (Ichilov)
  • O Dr. Yair é especializado em hematologia, com foco na leucemia linfoide crônica – reconhecido com múltiplos prêmios por sua pesquisa e excelência clínica.

    • Ganhador do Prêmio de Oncologia Klitzberg e outras honras de prestígio
    • Membro das Associações de Hematologia Israelense e Americana
    • Treinamento realizado nos principais centros médicos de Israel
    • Publicado extensivamente em pesquisa em hematologia
  • Leia mais
Consulta médica
Preço sob consulta
Info

Tahsin Ozatli

  • 4.2 Bom • 19 avaliações
  • 2016 anos de experiência
  • Turquia, Istambul, Istinye University Liv Hospital Bahcesehir
  • O Dr. Tahsin Ozatli especializa-se em cancros da mama, pulmão e gastrointestinais, trazendo uma experiência focada em tratamentos de imunoterapia.

    • Professor associado desde 2016
    • Experiência em vários departamentos de oncologia na Turquia
    • Graduado pela Faculdade de Medicina da Universidade de Selcuk
  • Leia mais
Consulta médica
Preço sob consulta
Info

Muhammed Mustafa Atci

  • 5 Excelente • 1 avaliações
  • 15 anos de experiência
  • Turquia, Istambul, İstinye University Liv Hospital Topkapı
  • O Professor Associado Muhammed Mustafa Atci é especializado em oncologia médica no Hospital İstinye University Liv Topkapı, com um forte foco em tratamentos de imunoterapia.

    • Membro da Sociedade Americana de Oncologia Clínica (ASCO)
    • Publicou vários artigos revisados por pares sobre os resultados do tratamento do câncer
    • Coordenador de educação para a subespecialidade de oncologia médica
    • Ampla experiência no tratamento de vários tipos de câncer com imunoterapia
  • Leia mais
Consulta médica
Preço sob consulta
Info

Mustafa Serkan Alemdar

  • 4.6 Excelente • 7 avaliações
  • 20 anos de experiência
  • Turquia, Antália, Medical Park Antalya Hospital Complex
  • O Dr. Alemdar especializa-se em imunoterapia com Keytruda no complexo hospitalar Medical Park Antalya, trazendo uma vasta experiência em oncologia médica.

    • Certificado em oncologia médica desde 2018
    • Mais de _doctor_9570_ anos de experiência em medicina interna e oncologia
    • Trabalhou no Hospital Universitário Akdeniz, uma instituição médica de referência
  • Leia mais
Consulta médica
Preço sob consulta
Info

Irfan Cicin

  • Médico líder em Imunoterapia com Keytruda (Pembolizumab)
  • 5 Excelente • 1 avaliações
  • 29 anos de experiência
  • Turquia, Istambul, İstinye University Liv Hospital Topkapı
  • O Professor Cicin especializa-se em imunoterapia no İstinye University Liv Hospital Topkapı, com mais de 29 anos de experiência em oncologia médica.

    • Formação especializada em oncologia médica na Universidade de Trakya
    • Professor na Faculdade de Medicina da Universidade de Trakya
    • Vasta experiência no tratamento de pacientes com cancro através de imunoterapia
  • Leia mais
Consulta médica
Preço sob consulta
Info

Ercan Ozden

  • 3 Bom • 2 avaliações
  • 27 anos de experiência
  • Turquia, Istambul, VM Medical Park Pendik Hospital
  • O Dr. Ozden traz mais de _doctor_10151_anos_ de experiência em oncologia médica para o seu papel no Hospital VM Medical Park Pendik.

    • Especializado em Oncologia Médica na Universidade de Kocaeli
    • Graduado pelo programa médico em inglês da Universidade de Istambul
    • Trabalhou em vários hospitais especializando-se em medicina interna
  • Leia mais
Consulta médica
Preço sob consulta
Info

Li Gui Yuan

  • Novo
  • 23 anos de experiência
  • China, Xangai, Centro de hematologia e terapia celular Shanghai Tongji Hospital
  • Li Guiyuan, MD, is Chief Physician in the Department of Medical Oncology at Shanghai Tongji Hospital. He has practiced oncology since 1996 and has more than 20 years of experience. He earned a master’s degree in Oncology from Nanjing University in 2003. He has worked in the hospital’s Oncology Department since then.

    His clinical work includes chemotherapy for lung, breast, ovarian, and gastrointestinal cancers. He also provides targeted and anti‑angiogenic therapies for malignant tumours. He manages malignant pleural and peritoneal effusions and bone metastases with multimodal care, including immunotherapy.

    He has authored more than 10 basic and clinical papers, including “Tumour Hypoxia and Its Therapeutic Strategies” and “Establishment of Tumour Model with B16 Melanoma Cell Line of C57BL/6 Mice in ICR Mice.” He received the Medical Achievement Award from the General Logistics Department of the PLA for “Research and Application of Early‑diagnosis and Prediction Model for Metastasis of Non‑small‑cell Lung Cancer.” He co‑authored “Evidence‑based Oncology Treatment” and “Handbook of Modern Evidence‑based Diagnosis and Treatment of Cancer.” He has also taken part in key projects of the National Natural Science Foundation of China.

  • Leia mais
Consulta médica
Preço sob consulta
Info

Yasemin Altuner Torun

  • 4.2 Bom • 19 avaliações
  • 25 anos de experiência
  • Turquia, Istambul, Istinye University Liv Hospital Bahcesehir
Consulta médica
Preço sob consulta
Info

Auala Hubert

  • 4.2 Bom • 13 avaliações
  • 36 anos de experiência
  • acreditações:
  • Israel, Jerusalém, Hadassah Medical Center
  • O Dr. Auala Hubert traz 36 anos de experiência em oncologia e radioterapia no Hadassah Medical Center, especializando-se em imunoterapia.

    • Chefia o Centro de Câncer Gastrointestinal – profunda experiência em casos complexos
    • Formado no Hadassah University Hospital – um dos principais centros de oncologia de Israel
    • Membro ativo de vários comitês de pesquisa e tratamento de câncer
  • Leia mais
Consulta médica
Preço sob consulta
Info

Wolfgang Schröder

  • 25 anos de experiência
  • Alemanha, Wuppertal, Helios Gesundheit
Consulta médica
Preço sob consulta
Info

Raanan Berger

  • 5 Excelente • 2 avaliações
  • 27 anos de experiência
  • Israel, Ramat Gan, Centro Médico Sheba
  • O Dr. Raanan Berger é o diretor do Centro de Câncer do Sheba Medical Center. Ele foi incluído na lista de "Melhores Médicos" da Forbes Israel em 2025. O Dr. Berger é especializado em oncologia geniturinária e trata tumores complexos de próstata com radioterapia. Ele completou um pós-doutorado no Dana-Farber/Harvard Cancer Institute.

    • Chefia a unidade de pesquisa clínica focada em oncologia molecular.
    • Coautor de mais de 20 artigos revisados por pares sobre câncer de próstata e mutações BRCA.
    • Membro da Sociedade Americana de Oncologia Clínica (ASCO).
    • Realiza terapia sistêmica e radioterapia em um hospital classificado entre os 10 melhores do mundo.
  • Leia mais
Consulta médica
Preço sob consulta
Info

Jair Bar

  • 5 Excelente • 2 avaliações
  • 35 anos de experiência
  • Israel, Ramat Gan, Centro Médico Sheba
  • O Dr. Jair Bar é oncologista torácico e vice-diretor do Centro de Câncer do Sheba Medical Center. Ele é especializado no tratamento de câncer de pulmão de células não pequenas avançado usando imunoterapia personalizada e tratamentos direcionados. O Dr. Bar possui doutorado em Biologia Molecular e lidera um laboratório de pesquisa focado em resistência à imunoterapia.

    • Presidente do Grupo Israelense de Câncer de Pulmão.
    • Certificado em Oncologia Médica e Radioterapia Oncológica.
    • Trata pacientes no Sheba Medical Center, um dos 10 melhores hospitais do mundo.
    • Usa perfil molecular e genético para criar planos precisos de tratamento contra o câncer.
  • Leia mais
Consulta médica
Preço sob consulta
Info

Eytan Aharon Ben-ami

  • 5 Excelente • 2 avaliações
  • 20 anos de experiência
  • Israel, Ramat Gan, Centro Médico Sheba
  • O Dr. Eytan Aharon Ben-Ami lidera a Divisão de Oncologia no Centro Médico Sheba, em Israel. Especializou-se em sarcomas e oncologia óssea no Dana-Farber Cancer Institute. O Dr. Ben-Ami fundou a Organização de Pesquisa Clínica Sheba para promover estudos sobre o câncer. Ele trata tumores ósseos raros e sarcomas de tecidos moles com protocolos personalizados.

    • Chefia a Unidade de Ensaios Clínicos de Fase Inicial para terapias inovadoras contra o câncer.
    • Autor de mais de 40 publicações científicas sobre mecanismos moleculares e detecção precoce.
    • Lidera ensaios de Fase I em terapia direcionada e imunoterapia para cânceres raros.
    • Trabalha no Centro Médico Sheba, um dos 10 melhores hospitais do mundo segundo a Newsweek.
  • Leia mais
Consulta médica
Preço sob consulta
Info

Francesc Bosch

  • 4.4 Bom • 6 avaliações
  • 126 anos de experiência
  • Espanha, Barcelona, Hospital Quiron Barcelona
  • O Professor Bosch lidera a pesquisa global em leucemia linfocítica crônica (LLC) e tratamentos de linfoma, com mais de 80 ensaios clínicos ativos.

    • Especialista em linfomas e LLC no Hospital Quiron Barcelona
    • Publicou mais de 100 artigos em periódicos de alto impacto como NEJM e Nature Medicine
    • Chefe de Hematologia no Hospital Universitário Vall d'Hebron
    • Desenvolve novas abordagens terapêuticas para distúrbios linfoproliferativos
  • Leia mais
Consulta médica
Preço sob consulta
Info

Zhang Jinshan

  • 41 anos de experiência
  • 50000+ tratamentos realizados
  • China, Chengdu, uni-asia hospital
  • Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

    1980–1985: Completed doctoral studies at Nagasaki University, Japan

    1968–present: Department of Radiology, Chinese PLA General Hospital

    1988: Third Prize of the Military Science and Technology Progress Award

    1989–present: Member of Radiological Society of North America(RSNA)

    1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

    1991: Second Prize of the Military Science and Technology Progress Award

    1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

    1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

    1993: Granted the Lifetime Special Government Allowance of the State Council

    1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

    1994: Third Prize of the Military Science and Technology Progress Award

    1997: Second Prize of the Military Science and Technology Progress Award

    1997–2009: Standing Member of Chinese Society of Radiology

    1999: Third Prize of the Military Science and Technology Progress Award

    1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

    2002: Second Prize of the Military Science and Technology Progress Award

    2005: Third Prize of the Military Science and Technology Progress Award

    Member of Radiological Society of North America(RSNA)

    Standing Member of Chinese Society of Radiology

    Group Leader of the Group of Intervention of Chinese Journal of Radiology

    Deputy Director Member of Chinese Society of Interventional Oncology

    Director Member of Beijing Medical Association Society of Interventional Radiology

    Deputy Chief Editor of Chinese Journal of Medical Image Technology

    Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

    Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

    Awarded the Special Government Allowance of the State Council

    Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

    Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

    Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

    In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

    zhang-jin-shan

    Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

    zhang-jin-shan

    In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

    zhang-jin-shan

    Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

    zhang-jin-shan

    From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

    Professor Zhang Jinshan’s Academic Achievements

    Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

    Selected Publications by Professor Zhang Jinshan

    1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993,27(6):361-365.

    Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

    2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996,30(8):521-524.

    Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

    3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998,14(3):189-191.

    Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

    4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000,34(5):335-337.

    Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

    5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002,36(7):612-614.

    Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

    6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004,20(9):1395-1397.

    Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

    7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006,40(8):876-878.

    Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

    8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008,28(10):856-858.

    Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

    Professor Zhang Jinshan co-authored monographs

    1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

    2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

    3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

    Professor Zhang Jinshan’s Research project

    1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

    2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

    3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

    4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

  • Leia mais
Consulta médica
Preço sob consulta
Info

Nir Peled

  • 4 Bom • 1 avaliações
  • acreditações:
  • Israel, Herzliya, Herzliya Medical Center
  • Especialista líder de Israel em imunoterapia para câncer de pulmão – o Prof. Peled chefia a Unidade de Câncer Torácico no Davidoff Cancer Center.

    • Especialista em Medicina Interna, Pneumologia e Oncologia Médica
    • Vencedor do prêmio ASCO MERIT por pesquisa de destaque
    • Chefe da Unidade de Pesquisa e Detecção de neoplasias torácicas no Sheba Medical Center
    • Presidente do Comitê de Detecção Precoce e Prevenção da IASLC
  • Leia mais
Consulta médica
Preço sob consulta
Info

Gil Bar-Sela

  • 5 Excelente • 2 avaliações
  • Israel, Haifa, Rambam Medical Center
  • Subdiretor do Departamento de Oncologia do Centro Médico Rambam – O Dr. Bar-Sela é especializado em tratamentos oncológicos de ponta.

    • Especialista em imunoterapia com Keytruda (pembrolizumab)
    • Focado em planos de tratamento oncológico personalizados
    • Trabalha num departamento de oncologia líder em Israel
  • Leia mais
Consulta médica
Preço sob consulta
Info

Alexander Hauswirth

  • 27 anos de experiência
  • Áustria, Viena, JUVENIS
  • Assoc. Prof. Priv.-Doz. Dr. Alexander W. Hauswirth is a specialist in internal medicine and haemato‑oncology at JUVENIS. Since 2010, he has served as the lead senior physician for Haematology/Haemostaseology and Oncology at the Clinic for Internal Medicine I, Medical University of Vienna/AKH Vienna, Austria’s largest hospital.

    He earned his medical degree from the University of Vienna in 1999. He received the venia docendi in 2010 and was appointed Associate Professor in 2012. He completed an additional haemato‑oncology qualification in 2014. As a Schrödinger Fellow in Salamanca in 2009–2010, he researched CLL stem and precursor cells. He has published regularly since 2000.

    Accreditations include Austrian Medical Chamber diplomas in emergency medicine (since 2009) and sports medicine (2018). Awards include the Schrödinger Fellowship (2009), the ÖGHO award (2009), and the European Society of Chemotherapy poster award (2003). Clinical focus: anaemias, leukaemias, lymph node disorders, clotting and anticoagulation, and pre‑operative clearance. Languages: German and English.

  • Leia mais
Consulta médica
Preço sob consulta
Info

Ella Tepper

  • 4.4 Bom • 13 avaliações
  • Israel, Telavive, Assuta Medical Center
  • Médico-chefe do Centro de Oncologia do Centro Médico Assuta, especializado em tratamentos de imunoterapia.

    • Oncologista com vasta experiência em terapias direcionadas
    • Lidera uma equipe dedicada a tratamentos avançados contra o câncer
    • Foca em planos de tratamento personalizados para pacientes
  • Leia mais
Consulta médica
Preço sob consulta
Info

Mariam Mohammed Hussein Abu Zeid

  • 17 anos de experiência
  • Egito, Cairo, Hospitais oncológicos internacionais Shefaa Al Orman
  • A Dra. Mariam Abu Zeid é oncologista clínica nos hospitais oncológicos internacionais Shefaa Al Orman. Ela é certificada pela Sociedade Europeia de Oncologia Médica (ESMO). A Dra. Abu Zeid trata tumores sólidos e cânceres hematológicos. Ela possui doutorado (Ph.D.) em Oncologia Clínica e Medicina Nuclear pela Universidade Ain Shams.

    • Administra quimioterapia, imunoterapia e tratamentos direcionados para vários tipos de câncer.
    • Supervisiona ensaios clínicos oncológicos e gerencia toxicidades relacionadas ao tratamento.
    • Coordena o atendimento ao paciente dentro de equipes multidisciplinares para estadiamento e diagnóstico complexos.
    • Atua em um centro credenciado pela ESMO que trata aproximadamente 6.000 pacientes anualmente.
  • Leia mais
Imunoterapia com Keytruda (Pembolizumab)
$1,500 - $1,550
Info